Accelerating Biomarker Discovery with Multi-Agent AI

AI-driven, multi-agent systems are transforming cancer biomarker discovery by enabling complex, end-to-end scientific workflows. AstraZeneca shares how they leverage these capabilities to scale insights enhance collaboration, and accelerate decision-making across oncology research.